Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center of Biotherapy, Chengdu, China.
FEBS Lett. 2020 Jan;594(1):199-204. doi: 10.1002/1873-3468.13566. Epub 2019 Aug 16.
Microtubules are composed of αβ-tubulin heterodimers, and drugs that interfere with microtubule dynamics are used widely in cancer chemotherapy. Small synthetic molecules with an indole nucleus as a core structure have been identified as microtubule inhibitors and recognized as anticancer agents. However, structural information for the interactions between indole derivatives and tubulin is sparse. Here, we present the 2.55 Å crystal structure of tubulin in complex with the indole derivative D64131. We compare the binding modes of D64131, colchicine, and five other indole derivatives to tubulin. These results reveal the interactions between the indole derivatives and tubulin, explain previous results of structure-activity-relationship (SAR) studies and, thus, provide insights into the development of new indole derivatives targeting the colchicine binding site.
微管由αβ-微管蛋白异二聚体组成,干扰微管动力学的药物广泛用于癌症化疗。具有色氨酸核作为核心结构的小分子合成物已被鉴定为微管抑制剂,并被认为是抗癌药物。然而,色氨酸衍生物与微管蛋白之间相互作用的结构信息很少。在这里,我们展示了与色氨酸衍生物 D64131 结合的微管蛋白的 2.55 Å 晶体结构。我们比较了 D64131、秋水仙素和其他五种色氨酸衍生物与微管蛋白的结合模式。这些结果揭示了色氨酸衍生物与微管蛋白之间的相互作用,解释了先前的结构-活性关系(SAR)研究结果,从而为开发针对秋水仙碱结合位点的新型色氨酸衍生物提供了思路。